IMV Inc. IMVIF

IMVIF Company Overview

IMV Inc. is a Canadian biotechnology company focused on the development of immunotherapies and vaccines using its proprietary lipid-based delivery platform known as DPX. The company has historically operated within the biotechnology and pharmaceutical research industries, with a primary emphasis on oncology and infectious disease applications. IMV’s development programs have centered on activating targeted immune responses through T-cell–based therapies, particularly in hematologic cancers and solid tumors.

The company’s principal value driver has been its DPX platform technology, which was designed to improve antigen delivery and sustain immune activation. IMV’s lead clinical candidate was Maveropepimut-S (MVP-S), previously studied in ovarian cancer and diffuse large B-cell lymphoma. IMV was founded in Canada and evolved from vaccine research initiatives into a clinical-stage immuno-oncology company listed on public markets in both Canada and the United States. Public disclosures and court-related filings indicate that the company experienced significant financial distress beginning in 2023, including creditor protection proceedings and restructuring activities. Certain aspects of the company’s current operating status are data inconclusive based on available public sources.